Menu

Former Wayne State Cancer Researcher Lodges 19th Retraction

Fazlul Sarkar had unsuccessfully sued PubPeer to reveal the identity of a commenter who accused him of research misconduct.

Jan 2, 2018
Shawna Williams

PIXABAY, DELPHINMEDIAA cancer researcher formerly found by a Wayne State University investigative committee to have engaged in research misconduct has racked up his 19th paper retraction, Retraction Watch reports. The retired pathologist, Fazlul Sarkar, had gained notoriety both for the investigation’s results and for his unsuccessful 2016 lawsuit against PubPeer, which sought to force the online discussion site to reveal the identity of commenters who alleged misconduct on his part.

See “PubPeer Wins Appeal on Anonymous Comments

The new retraction, dated December 22, is of a 2012 study in Cancer Letters titled “Increased Ras GTPase activity is regulated by miRNAs that can be attenuated by CDF treatment in pancreatic cancer cells.” The retraction notice explains that the Wayne State investigation found a discrepancy between the originally collected data and those reported in two of the paper’s figures.

The 2015 Wayne State report recommended that 42 of Sarkar’s papers be retracted—of those, more than half remain intact, Retraction Watch notes.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.